Eversept Partners, LP Syndax Pharmaceuticals Inc Transaction History
Eversept Partners, LP
- $904 Million
- Q1 2025
A detailed history of Eversept Partners, LP transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Eversept Partners, LP holds 4,212,270 shares of SNDX stock, worth $47 Million. This represents 5.73% of its overall portfolio holdings.
Number of Shares
4,212,270
Previous 343,400
1126.64%
Holding current value
$47 Million
Previous $4.54 Million
1040.52%
% of portfolio
5.73%
Previous 0.46%
Shares
17 transactions
Others Institutions Holding SNDX
# of Institutions
240Shares Held
101MCall Options Held
1.36MPut Options Held
618K-
Kynam Capital Management, LP Princeton, NJ8.52MShares$95.1 Million8.82% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$88.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.87MShares$54.4 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.01MShares$44.7 Million0.12% of portfolio
-
State Street Corp Boston, MA3.97MShares$44.3 Million0.0% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $631M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...